TP0463518

12/01/2019 - "The present study revealed that TP0463518 specifically induced EPO production in the liver and improved anemia. "
12/01/2019 - "Investigation of the effects of TP0463518 may pave the way for the development of a new therapeutic alternative for renal anemia patients."
12/01/2019 - "The characteristic feature of TP0463518 would lead to not only a more detailed understanding of the PHD-HIF2α-EPO pathway in erythropoiesis, but a new therapeutic alternative for renal anemia. "
01/01/2018 - "These results suggest that TP0463518 is a new strategy for treating anemia in CKD, which can be used regardless of renal functions."
01/01/2021 - "While TP0463518 has been shown to improve renal anemia, its effect on anemia of inflammation is still unknown. "

01/01/2021 - "Furthermore, TP0463518 had no effect on the expressions of inflammation markers in the liver. "
01/01/2021 - "While TP0463518 has been shown to improve renal anemia, its effect on anemia of inflammation is still unknown. "
01/01/2021 - "TP0463518 appears to have an acceptable safety profile and could become a useful new therapeutic option for anemia of inflammation."
01/01/2021 - "These results suggest that TP0463518 increased iron absorption and improved anemia of inflammation without exacerbating liver inflammation. "
01/01/2021 - "TP0463518 (TS-143) Ameliorates Peptidoglycan-Polysaccharide Induced Anemia of Inflammation in Rats."

07/01/2022 - "1. TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, is reportedly excreted predominantly through urinary excretion in an unchanged form in humans, with partial biliary excretion also possible. "
07/01/2022 - "Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?"
12/01/2019 - "We examined the effect of TP0463518 in inducing EPO production in the kidney and liver by measuring the hypoxia-inducible factor 2α (HIF-2α), EPO mRNA, and serum EPO levels in normal and bilaterally nephrectomized rats. "
01/01/2021 - "TP0463518 (TS-143) is a competitive prolyl hydroxylase 1/2/3 pan-inhibitor, and has been shown to specifically stabilize hypoxia-inducible factor-2 alpha in the liver to increase erythropoietin production. "
11/05/2018 - "TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation."

11/05/2018 - "TP0463518 also increased the serum EPO level in 5/6 nephrectomized chronic kidney disease model rats at a dose of 10 mg/kg, with a correlation factor for serum EPO and the serum TP0463518 levels of 0.82. "
01/01/2018 - "TP0463518 is a novel hypoxia-inducible factor prolyl hydroxylase inhibitor developed to aid in the treatment of anemia associated with chronic kidney disease (CKD) and is expected to increase erythropoietin (EPO) derived from liver. "